Cardiac Resynchronization Therapy With Defibrillator for Acromegalic Cardiomyopathy With Left Bundle Branch Block Authors: Jin Bai, Zhi Shang, Ming Cui, Shuwang Liu Published: 2026 ABSTRACT BackgroundHeart failure is a cardiovascular complication of acromegaly associated with poor prognosis. Treatment directed solely at acromegaly does not reliably improve cardiac function.Case SummaryA 56-year-old man was diagnosed with acromegaly and acromegalic cardiomyopathy. After 6 months of somatostatin analog therapy combined with guideline-directed medical therapy for heart failure, his left ventricular ejection fraction and hormone level improved. Subsequently, the patient developed acute heart failure triggered by sustained ventricular tachycardia. The patient received cardiac resynchronization therapy with defibrillator. During follow-up, the patient had no further heart failure exacerbations; echocardiography showed left ventricular ejection fraction increased to 48%. His left ventricular synchrony improved markedly.DiscussionNormalization of growth hormone levels does not fully reverse myocardial involvement in this patient with advanced acromegalic cardiomyopathy. In this patient, cardiac resynchronization therapy significantly improved left ventricular synchrony and outcome.Take-Home MessageThis case highlights the importance of timely and appropriate cardiac resynchronization therapy with defibrillator implantation in patients with advanced acromegalic cardiomyopathy. History of Presentation A 56-year-old man was admitted to our hospital. He suffered from intermittent dyspnea for 7 months and had experienced palpitations and dizziness for 1 week before being hospitalized. Seven months ago, the patient developed dyspnea without any obvious cause, which was more pronounced when lying flat and relieved after sitting up for 2 minutes. He was 160 cm tall, weighed 60 kg, and his body mass index was 23.44 kg/m2. The patient has no other complaints of discomfort. There was no visual field defect or decreased vision. His electrocardiogram in another hospital before being admitted to our hospital showed complete left bundle branch block, and echocardiography showed left ventricular enlargement and reduced left ventricular ejection fraction (LVEF) (16%). Coronary computed tomography angiography showed a mid-segment myocardial bridge of the left anterior descending artery. For further diagnosis and treatment, the patient was referred to our hospital. The patient displayed acromegalic facial features: prognathism, widened nasal alae, enlarged lips, enlarged hands and feet with thickened finger and toe joints, thoracic deformity, and a depression at the xiphoid process (Figure 1). In his family, his brother and 2 sisters also had enlarged lips.Take-Home Message•This case highlights the importance of timely and appropriate CRT-D implantation in patient with advanced acromegalic cardiomyopathy.Figure 1Physical and Facial Manifestations of the Acromegaly Patient Take-Home Message •This case highlights the importance of timely and appropriate CRT-D implantation in patient with advanced acromegalic cardiomyopathy. •This case highlights the importance of timely and appropriate CRT-D implantation in patient with advanced acromegalic cardiomyopathy. This case highlights the importance of timely and appropriate CRT-D implantation in patient with advanced acromegalic cardiomyopathy. Physical and Facial Manifestations of the Acromegaly Patient Past Medical History He was diagnosed with hypertension for 6 years, with his highest blood pressure at 150/100 mm Hg. The patient was taking 1 tablet of valsartan-hydrochlorothiazide once daily for blood pressure control. Blood pressure was maintained around 120/80 mm Hg. One year ago, he was diagnosed with severe obstructive sleep apnea and has been prescribed home continuous positive airway pressure therapy. He smoked 20 cigarettes every day for 20 years and consumed alcohol for 30 years, twice a week, 250 mL of 53-degree liquor each time. He had been alcohol-free for 6 years. His father and 1 sister died from heart failure. Differential Diagnosis The differential diagnosis included the following: coronary atherosclerotic cardiopathy; hypertension; dilated cardiomyopathy; and heart valve disease. Investigations In the emergency department, his electrocardiograph showed complete left bundle branch block (Figure 2). Echocardiography demonstrated diffuse left ventricular hypokinesis, left ventricular dyssynchrony, left ventricular wall thickening, left ventricular dilation (LVEDD) (80 mm), and LVEF of 25%. Coronary computed tomography angiography showed no coronary artery stenosis.Figure 2Electrocardiograph(A) Admission electrocardiograph demonstrating complete left bundle branch block with a QRS duration of 162 milliseconds. (B) Post–cardiac resynchronization therapy with defibrillator electrocardiograph, with the QRS duration reduced to 110 milliseconds. Electrocardiograph (A) Admission electrocardiograph demonstrating complete left bundle branch block with a QRS duration of 162 milliseconds. (B) Post–cardiac resynchronization therapy with defibrillator electrocardiograph, with the QRS duration reduced to 110 milliseconds. In combination with the patient's acromegalic facial features, after admission, the following tests were completed: growth hormone (GH) (12.7 ng/mL; reference value: <3 ng/mL); insulin-like growth factor (332 ng/mL; reference value: 45-210 ng/mL); positive high glucose suppression test; and sex hormones (prolactin: 8.4 ng/mL; follicle stimulating hormone: 6.86 mIU/mL; luteinizing hormone: 7.19 mIU/mL; testosterone T: 17.7 nmol/L; progesterone P: 0.77 nmol/L). The patient also had normal adrenocorticotropic hormone–cortisol rhythm (8 am, 4 pm, 24:00 am), free cortisol (24-hour urine) measurement, and normal thyroid function. Electrocardiogram showed sinus rhythm and complete left bundle branch block (QRS interval: 162 milliseconds). Dynamic electrocardiogram showed occasional premature ventricular contractions and short runs of ventricular tachycardia. The enhanced brain magnetic resonance scan revealed a microadenoma in the anterior lobe of the pituitary gland (8.3 × 4.7 × 6.2 mm). Markedly elevated GH and insulin-like growth factor-1 levels, a positive oral glucose suppression test, and the detection of a pituitary microadenoma on magnetic resonance imaging established the diagnosis of acromegaly. Management The patient met surgical indications, but the patient's current cardiac function was not capable of withstanding the surgery. Therefore, he was administered lanreotide treatment. In terms of heart failure treatment, he was administered metoprolol 6.25 mg twice daily, spironolactone 20 mg once daily, dapagliflozin 10 mg once daily, and vericiguat 5 mg once daily to improve his prognosis. Outcome and Follow-Up After 6 months of somatostatin analog therapy combined with guideline-directed medical therapy for heart failure, his LVEF gradually rose to 35% and LVEDD gradually decreased to 74.8 mm (Table 1).Table 1First Hospitalization, CRT-D, and Follow-Up Data After DischargeFirst AdmissionVisit 1Visit 2Visit 3Visit 4Admission for CRT-D After ExacerbationVisit After CRT-DVisit 1Visit 2Visit 3Visit 4Visit 5Visit 6Visit 7Visit 8Lanreotide, mg909090120120120120120120120120120120120LVEF, %16282835263030323938454850LVEDD, mm86.577.579.474.883.460.8676061.456.7585855.3NT-proBNP, pg/mL6077425594593695051856969655725<10GH, ng/mL13.93.832.54.343.742.742.62.63.333.222.49IGF-1, ng/mL358268285296293303296288299281349CRT-D = cardiac resynchronization therapy with defibrillator; GH = growth hormone; IGF-1 = insulin-like growth factor-1; LVEDD = left ventricular dilation; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro–B-type natriuretic peptide. Table 1First Hospitalization, CRT-D, and Follow-Up Data After DischargeFirst AdmissionVisit 1Visit 2Visit 3Visit 4Admission for CRT-D After ExacerbationVisit After CRT-DVisit 1Visit 2Visit 3Visit 4Visit 5Visit 6Visit 7Visit 8Lanreotide, mg909090120120120120120120120120120120120LVEF, %16282835263030323938454850LVEDD, mm86.577.579.474.883.460.8676061.456.7585855.3NT-proBNP, pg/mL6077425594593695051856969655725<10GH, ng/mL13.93.832.54.343.742.742.62.63.333.222.49IGF-1, ng/mL358268285296293303296288299281349CRT-D = cardiac resynchronization therapy with defibrillator; GH = growth hormone; IGF-1 = insulin-like growth factor-1; LVEDD = left ventricular dilation; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro–B-type natriuretic peptide. First Hospitalization, CRT-D, and Follow-Up Data After Discharge CRT-D = cardiac resynchronization therapy with defibrillator; GH = growth hormone; IGF-1 = insulin-like growth factor-1; LVEDD = left ventricular dilation; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro–B-type natriuretic peptide. However, 1 week earlier, the patient developed acute heart failure triggered by sustained ventricular tachycardia. Echocardiography revealed an enlarged LVEDD of 83.4 mm and a reduced LVEF of 26%. Furthermore, a peak strain dispersion of 193.8 milliseconds (normal: <36 milliseconds) (Figure 3), a septal-to-posterior wall motion delay of 350 milliseconds (normal: <130 milliseconds), and a septal-to-lateral wall motion delay of 365 milliseconds (normal: <130 milliseconds) was revealed, indicating marked left ventricular wall motion dyssynchrony. GH levels had returned to normal. The patient met indications for cardiac resynchronization therapy with defibrillator (CRT-D) and underwent CRT-D implantation during the second hospitalization after his exacerbation (Figure 4). Postoperatively, the QRS duration narrowed to 110 milliseconds (Figure 2B).Figure 3Speckle-Tracking EchocardiographyThe peak strain dispersion was 193.8 milliseconds, indicating irregular left ventricular motion. ANT = anterior wall; ANT SEPT = anteroseptal; GS = global strain; INF, inferior wall; LAT = lateral wall; POST = posterior wall.Figure 4Postoperative Chest Radiograph After Cardiac Resynchronization Therapy With Defibrillator Shows the Pacing Leads in Good Position Speckle-Tracking Echocardiography The peak strain dispersion was 193.8 milliseconds, indicating irregular left ventricular motion. ANT = anterior wall; ANT SEPT = anteroseptal; GS = global strain; INF, inferior wall; LAT = lateral wall; POST = posterior wall. Postoperative Chest Radiograph After Cardiac Resynchronization Therapy With Defibrillator Shows the Pacing Leads in Good Position During the follow-up period after CRT-D implantation, the patient had no further heart failure exacerbations; echocardiography showed LVEDD reduced to 55.3 mm, and LVEF increased to 50%. His left ventricular synchrony improved markedly, with peak strain dispersion decreasing to 80 milliseconds, septal-to-posterior wall motion delay decreasing to 76 milliseconds, and septal-to-lateral wall motion delay decreasing to 0 milliseconds. Before the surgery, he could only climb 1 floor and continue climbing after resting. One month after the surgery, he could climb 3 floors. In the most recent follow-up, the patient could climb 5 floors without resting.Visual SummaryTimeline for the CaseCRT-D = cardiac resynchronization therapy with defibrillator; GH = growth hormone; IGF-1 = insulin-like growth factor-1; LVEF = left ventricular ejection fraction. Timeline for the Case CRT-D = cardiac resynchronization therapy with defibrillator; GH = growth hormone; IGF-1 = insulin-like growth factor-1; LVEF = left ventricular ejection fraction. Discussion GH is involved in regulating vital activities, including cardiac growth, myocardial contractility, and the vascular system. It exerts effects by stimulating the production of insulin-like growth factor-1.1,2 Excessive secretion GH and insulin-like growth factor-1 in acromegaly have a variety of effects on cardiovascular, respiratory, endocrine, metabolic, musculoskeletal, and neoplastic comorbidities. Patients with acromegaly usually experience abnormal growth of bone and soft tissue and abnormal glucose metabolism, which may result in cardiovascular complications and higher mortality risk.3, 4, 5 GH and insulin-like growth factor-1 directly affect cardiac activities.6 Cardiovascular complications are a common cause of mortality in acromegaly, and undiagnosed acromegaly may be an underlying cause of sudden death.1,9 It has been reported that the standardized mortality ratio increases by 1.5 to 2.5 times in these patients (ie, the life expectancy of such patients who have not been cured decreases by approximately 10 years).7,8 One important factor that influences the progression of acromegaly and development of cardiovascular complications is a 5- to 10-year delay in the final diagnosis. The complications and external physical and facial changes in patients with acromegaly develop gradually. These changes may not be noticed by the patients themselves or their families.9,10 Previous studies have shown the rate of arrhythmia occurrence in patients with acromegaly ranges from 7% to 40%.2 Arrhythmias in patients with acromegaly can manifest in a wide variety of forms. Among all forms of arrhythmia, malignant ventricular tachyarrhythmia may be the primary cause of repeated syncope and sudden death because of cardiac comorbidities in acromegaly.11 Complex ventricular arrhythmia was more often observed in acromegaly than the general population.3 For most patients with acromegaly who meet the surgical indications, transsphenoidal neurosurgery is the primary choice. However, the efficacy of transsphenoidal neurosurgery depends on adenoma size, its expansion, and the neurosurgeon's experience to varying degrees. In patients who remain uncured after surgery and in those do not meet surgical indications, medical therapies are administered. Among medicine treatment therapy, somatostatin analogs are the first choice. Usually, a GH receptor antagonist (pegvisomant) or dopamine agonist (cabergoline) is used in monotherapy or given additionally to somatostatin analogs. Other treatment methods available include stereotactic radiotherapy (radiosurgery).12,13 From our data, medical therapy including somatostatin analog therapy brought improvement in this patient's cardiac function and hormone level at the beginning of the treatment, which stressed the benefit of somatostatin analog therapy. He did benefit from the treatment of the underlying disease. However, although the treatment reached a relatively satisfactory level, adverse cardiac events still occurred during this stage and led to a significantly reduced ejection fraction and arrhythmia. Moreover, he has a complete left bundle branch electrical structure abnormality in his heart. Thus, this condition may require further CRT-D to correct and ultimately achieve an improvement in cardiac function. He received intervention with CRT devices, along with the use of medicine for treatment. Parameters during follow-up confirmed that he had a relatively favorable outcome. Another successful case was reported previously in 2019. A 49-year-old man suffered from acromegaly and heart failure. His electrocardiograms showed a wide QRS wave (160-200 milliseconds) accompanied by left bundle branch block, and his echocardiography showed severe impairment of left ventricular function. Cardiac resynchronization therapy was performed. The patient's symptoms were finally relieved and he was discharged.14 In this context, it would be worth discussing whether earlier CRT-D implantation might have been more appropriate. Therefore, we hypothesize that for patients with acromegaly who have progressed to the stage of heart failure along with arrhythmias, despite etiologic treatment, active CRT intervention may be of great help in the patient's clinical symptoms and prognosis. Perhaps early CRT-D treatment can prevent adverse events. However, more research is needed to support the selection of patients suitable for CRT-D surgery because some patients can achieve a favorable outcome through drug treatment, whereas others have an increased risk of cardiac deterioration and thus require CRT-D therapy. Conclusions In some patients with advanced acromegalic cardiomyopathy, normalization of GH levels does not fully reverse myocardial involvement; therefore, pharmacologic HF therapy and device-based treatments are of great importance. In patients with concomitant left bundle branch block, left ventricular dyssynchrony is a major contributor to heart failure, and CRT can significantly improve left ventricular synchrony and patient outcomes. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.